OS Therapies (NYSE-A: OSTX), a clinical-stage biopharmaceutical company specializing in immunotherapy and Antibody Drug Conjugates, has announced the appointments of Avril McKean Dieser, MA, JD, and Olivier R. Jarry, MS, MBA, as independent members of its Board of Directors. Together, Ms. McKean Dieser and Mr. Jarry bring more than 50 years of executive experience in the biopharmaceutical industry, particularly in the commercialization of biologic products.
“OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors,” said Paul Romness, MHP, Chairman & CEO of OS Therapies. “Ms. McKean Dieser brings extensive experience in regulatory affairs, pricing, commercialization, and patient engagement, while Mr. Jarry offers significant business development and fundraising expertise. As we prepare to engage with the FDA regarding our potentially pivotal trial for the cancer immunotherapy OST-HER2, aimed at preventing metastasis in resected, recurrent osteosarcoma, we are enhancing our internal infrastructure for regulatory approval and commercial launch in the U.S., while exploring strategic partnerships for international market entry. Ms. McKean Dieser and Mr. Jarry are well-positioned to help us achieve these goals.”
Mr. Romness also expressed gratitude to Dr. Colin Goddard and Mr. Joacim Borg for their years of service, particularly in guiding OS Therapies through its transition to a public company.
Ms. McKean Dieser currently serves as Vice President, Head of Legal Patient Evidence at UCB, Inc., a global biopharmaceutical company. She leads a team supporting UCB’s global assets and payer functions, as well as regulatory and clinical development. Previously, she was part of AbbVie’s legal team, focusing on global product support for immunology and oncology, and served as the government pricing lawyer for pharmaceutical products. Before her pharmaceutical career, she practiced corporate law in Atlanta. Ms. McKean Dieser holds a J.D. from The Catholic University Columbus School of Law and has a background in public administration and English literature. She tragically lost her son Edward to osteosarcoma in January 2024.
“I am deeply grateful that OS Therapies’ mission is to bring to market the first new osteosarcoma treatment in over 40 years,” said Ms. McKean Dieser. “As a newly appointed director, I will focus on helping management implement its regulatory and commercialization plan so that OST-HER2 can ultimately reach patients and families in need of new solutions for this challenging childhood cancer.”
Mr. Olivier Jarry, the newly appointed independent Board member, noted, “OS Therapies presents a unique opportunity to introduce a novel cancer immunotherapy for the rare pediatric disease of osteosarcoma, which could also potentially change the standard of care for HER2-expressing cancers. The possibility of receiving a priority review voucher following approval for osteosarcoma, which could be sold to help fund the commercialization of OST-HER2, is compelling from both investment and product development perspectives. I am excited to support the Company in achieving its strategic objectives.”
Mr. Jarry is the Co-founder and CEO of Libera Bio S.L., a Spanish biopharmaceutical company focused on precision therapeutics for cancer. He also serves as COO of Advantage Therapeutics Inc. and CFO of Rational Vaccines, Inc. Previously, he was President and Chief Commercial Officer of DarioHealth and held various leadership roles at Intrexon Corp. and Bristol-Myers Squibb, where he oversaw product launches and growth in several therapeutic areas. Mr. Jarry holds multiple degrees, including an M.Sc. from Ecole Centrale de Paris and a Trium Executive MBA.
About OS Therapies
OS Therapies is a clinical-stage oncology company dedicated to developing and commercializing treatments for osteosarcoma and other solid tumors. Its lead asset, OST-HER2, is an immunotherapy that harnesses the immune-stimulatory effects of Listeria bacteria to target the HER2 protein. The company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in Q4 2024. OST-HER2 has also shown efficacy in a Phase 1 study primarily involving breast cancer patients and has received conditional approval from the U.S. Department of Agriculture for treating canines with osteosarcoma. Additionally, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which utilizes proprietary silicone linker technology to enable the delivery of multiple payloads.
